✦ LIBER ✦

A randomized phase II trial of platinum salts in basal-like breast cancer patients in the neoadjuvant setting. Results from the GEICAM/2006-03, multicenter study

✍ Scribed by E. Alba, J. I. Chacon, A. Lluch, A. Anton, L. Estevez, B. Cirauqui, E. Carrasco, L. Calvo, M. A. Segui, N. Ribelles, R. Alvarez, A. Sanchez-Muñoz, R. Sanchez, J. A. Lopez Garcia-Asenjo, C. Rodriguez-Martin, et al

Book ID: 118796642
Publisher: Springer US
Year: 2012
Tongue: English
Weight: 254 KB
Volume: 136
Category: Article
ISSN: 0167-6806
DOI: 10.1007/s10549-012-2100-y

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Chemotherapy (CT) and hormonotherapy (HT

Chemotherapy (CT) and hormonotherapy (HT) as neoadjuvant treatment in luminal breast cancer patients: results from the GEICAM/2006-03, a multicenter, randomized, phase-II study

✍ Alba, E.; Calvo, L.; Albanell, J.; De la Haba, J. R.; Arcusa Lanza, A.; Chacon, 📂 Article 📅 2012 🏛 Oxford University Press 🌐 English ⚖ 159 KB

The potential risk of neoadjuvant chemot

The potential risk of neoadjuvant chemotherapy in breast cancer patients—results from a prospective randomized trial of the Austrian Breast and Colorectal Cancer Study Group (ABCSG-07)

✍ Susanne Taucher; Guenther G. Steger; Raimund Jakesz; Christoph Tausch; Viktor We 📂 Article 📅 2007 🏛 Springer US 🌐 English ⚖ 252 KB

Effects of the ghrelin receptor agonist

Effects of the ghrelin receptor agonist anamorelin on lean body mass in cancer patients with cachexia; results from a Phase II randomized, double blind, multicenter study

✍ Garcia, Jose M; Yan, Ying; Manning-Duus, Elizabeth; Friend, John 📂 Article 📅 2014 🏛 BioMed Central 🌐 English ⚖ 79 KB

The added value of the combined evaluati

The added value of the combined evaluation of clinical efficacy, quality of life and cost-effectiveness in a randomized phase III study. Results of an EORTC — NCIC — SAKK neoadjuvant trial in patients with locally advanced breast cancer (LABC)

✍ Therasse, P.; Mauriac, L.; Welnicka, M.; Bruning, P.; Cufer, T.; Lichinitser, R. 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 132 KB

Final results of a multicenter phase II

Final results of a multicenter phase II clinical trial evaluating the activity of single-agent lapatinib in patients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells. A proof-of-concept study

✍ Marta Pestrin, Silvia Bessi, Fabio Puglisi, Alessandro M. Minisini, Giovanna Mas 📂 Article 📅 2012 🏛 Springer US 🌐 English ⚖ 246 KB

5002 ORAL Results from a Phase II random

5002 ORAL Results from a Phase II randomized, placebo-controlled, double-blind trial suggest improved PFS with the addition of pertuzumab to gemcitabine in patients with platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer

✍ Makhija, S.; Glenn, D.; Ueland, F.; Dizon, D.; Paton, V.; Lin, C.Y.; Amler, L.; 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 77 KB